UPDATE : Friday, September 20, 2019
상단여백
Court extends ‘temporary suspension’ of order to cancel Invossa trials by Jeong Sae-im 2019-07-26 17:50
SNUBH professor is 1st Asian keynoter at international Alzheimer meet by Lee Han-soo 2019-07-26 16:08
‘Kolon Life Science to start following up on Invossa-treated patients’ by Lee Han-soo 2019-07-26 12:21
JW Creagene wins US patent for making dendritic cell treatment by Lee Han-soo 2019-07-25 16:39
Merck, Pfizer launch metastatic merkel cell carcinoma treatment in Korea by Lee Han-soo 2019-07-25 15:18
라인
[Focus] Korean biopharmas eye US Humira market by Jeong Sae-im 2019-07-25 15:02
Kolon Life Science ends Invossa deal with Hong Kong partner by Lee Han-soo 2019-07-25 11:17
Tecentriq 1st immunotherapy to get coverage regardless of PD-L1 expression by Lee Han-soo 2019-07-24 11:59
Alteogen to develop growth hormone for children with Brazilian partner by Lee Han-soo 2019-07-23 15:57
Hanmi's US partner to expand Poziotinib clinical program by Lee Han-soo 2019-07-23 14:25
라인
Merck Biopharma Korea names new general manager by Lee Han-soo 2019-07-23 11:08
‘Doubts about biopharmaceutical-developing ability to change investment pattern’ by By Jeong Sae-im 2019-07-23 10:58
Will Gilead enter the autoimmune diseases market? by Kim Yun-mi 2019-07-22 17:34
Korean drugs strong in anti-reflux treatment market by Jeong Sae-im 2019-07-22 15:15
JW completes P1 trials for target anticancer treatment by Lee Han-soo 2019-07-22 14:02
라인
MedPacto passes tech assessment, seeks KOSDAQ listing this year by Jeong Sae-im 2019-07-19 17:01
Employees file suit against Galderma Korea by Kim Yun-mi 2019-07-19 15:41
‘Insurance benefits needed for Ibrance-fulvestrant combo treatment’ by Kim Yun-mi 2019-07-18 17:04
2 cancer immunotherapy makers face different situations in reimbursement talks by Kim Yun-mi 2019-07-18 16:01
Bridge Biotherapeutics licenses out IPF treatment candidate to Boehringer by Lee Han-soo 2019-07-18 15:58
여백
여백
여백
Back to Top